# of Displayed Technologies: 10 / 20

Applied Category Filter (Click To Remove): Therapeutics


Categories

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Flammang, Ann Marie

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Pyrrolopyrimidine Derivatives as Mps1/TTK Kinase Inhibitors for Cancer Therapy
TS-037724 — Small molecules for targeted treatment of triple negative breast cancer and other aggressive phenotypes.
Breast cancer is a heterogeneous group of tumors which can be subdivided based on histopathological features, genetic alterations, and gene-expression profiles. Approximately 50-60% of all breast cancer patients and two-thirds of postmenopausal breast cancer patients have estrogen receptor positiv…
  • College: College of Pharmacy
  • Inventors: Brueggemeier, Robert; Fisk, Harold; Li, Chenglong; Li, Pui-Kai "Tom"; Sugimoto, Yasuro
  • Licensing Officer: Davis, Stewart

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Flammang, Ann Marie

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Paschall, Christopher

Novel bacterial Type II topoisomerase inhibitors for the treatment of bacterial infections
TS-037293 — Bacterial infections such as sexually transmitted diseases, meningitis, pneumonia, tuberculosis (TB), and tetanus are some of the most common infectious diseases. However, there are few drugs that can be used against all of these diseases, and several bacteria have developed resistance to many com…
  • College: College of Pharmacy
  • Inventors: Mitton-Fry, Mark
  • Licensing Officer: Flammang, Ann Marie

Small-Molecule Cyclin D1 Ablative Agents for Breast Cancer Therapy
TS-015102 — A new class of small-molecule cyclin D1 ablative agents based on troglitazone (TG) that repress intracellular cyclin D1 levels.
Cyclin D1 represents an important downstream effector of diverse proliferative and transforming signaling pathways. In mammary cells, transcriptional activation of Cyclin D1 leads to G1/S phase progression and increased proliferation. Cyclin D1 overexpression has been implicated in oncogene-induce…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Huang, Jui-Wen
  • Licensing Officer: Paschall, Christopher

Show More Technologies

Loading icon